CSL Limited (CMXHF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Melbourne, VIC, Australia. El CEO actual es Gordon Naylor DipCompSc.
CMXHF tiene fecha de IPO 2005-11-18, 32,698 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $46.79B.
CSL Limited is a global biopharmaceutical company founded in 1916 and headquartered in Parkville, Australia. The company researches, develops, manufactures, and distributes biopharmaceutical products across Australia, the United States, Europe, China, and other international markets. Operating through two main divisions—CSL Behring and Seqirus—the company specializes in plasma-derived therapies for immunodeficiency, bleeding disorders, and neurological conditions, as well as non-plasma biotherapeutics and influenza-related products. CSL Behring also generates revenue through licensing and royalties on intellectual property commercialization.
